IBAT (apical sodium-bile acid transporter) inhibitor
Odevixibat
Brand names: Bylvay
Adult dose
Dose: Weight-based PO OD before breakfast; refer to BNF/SmPC
Route: PO
Frequency: OD
Clinical pearls
- Pruritus in PFIC and Alagille syndrome; specialist hepatology
Contraindications
- Decompensated cirrhosis
- Hypersensitivity
Side effects
- Diarrhoea
- Abdominal pain
- Hepatotoxicity
- Reduced fat-soluble vitamin absorption
Interactions
- Bile-acid sequestrants (separate)
Monitoring
- LFTs
- Vitamin A/D/E/INR
Reference: BNF; NICE; SmPC; https://bnf.nice.org.uk/drugs/odevixibat/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Corrected Sodium (Hyperglycaemia) · Electrolytes
- Hyponatraemia Cause Algorithm · Electrolyte Disorders
- MELD-Na Score · Liver Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
Pathways
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021